Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12350
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBoyapati, Rayen
dc.contributor.authorOng, Sim Yeen
dc.contributor.authorYe, Beien
dc.contributor.authorKruavit, Anuken
dc.contributor.authorLee, Noraen
dc.contributor.authorVaughan, Rhys Ben
dc.contributor.authorNandurkar, Sanjayen
dc.contributor.authorGibson, Peteren
dc.contributor.authorGarg, Mayuren
dc.date.accessioned2015-05-16T02:02:19Z
dc.date.available2015-05-16T02:02:19Z
dc.date.issued2014-08-14en
dc.identifier.citationWorld Journal of Gastroenterology; 20(30): 10504-11en
dc.identifier.govdoc25132768en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/12350en
dc.description.abstractTo calculate the proportion of potentially preventable hospitalizations due to peptic ulcer disease (PUD), erosive gastritis (EG) or duodenitis (ED).Retrospective cohort study using ICD-10 codes to identify all patients with upper gastrointestinal hemorrhage secondary to endoscopically proven PUD, EG or ED during the period from March 2007 to October 2010 in three major metropolitan hospitals in Melbourne, Australia. Patients were divided into "high risk" (those who would benefit from gastroprotection) and "not high risk" groups as defined by established guidelines. Mean Rockall score, transfusion requirement, length of stay, rebleeding rates, need for surgery and in-hospital mortality was compared between "high risk" and "not high risk" groups. Within the "high risk" group, those on gastroprotection and those with no gastroprotection were also compared.Five hundred and seven patients were included for analysis of which 174 were classified as high risk. Median values of complete Rockall Score (5 vs 4, P = 0.002) and length of stay (5 d vs 4 d, P = 0.04) were higher in the high risk group but in-hospital mortality was lower (0.6% vs 3.9%, P = 0.03). 130 out of the 174 patients in the high risk group were not taking recommended gastroprotective therapy prior to hospitalization. Past history of PUD (OR = 3.7, P = 0.006) and clopidogrel use (OR = 3.2, P = 0.007) significantly predicted prescription of gastroprotective therapy. Using proton pump inhibitor protection rates of 50%-85% from published studies, an estimation of 13% to 22% of the total number of the hospitalizations due to PUD or EG/ED related bleeding may have been preventable.Up to one fifth of all hospitalizations for bleeding secondary to PUD or EG/ED are potentially preventable.en
dc.language.isoenen
dc.subject.otherGastrointestinal hemorrhageen
dc.subject.otherGastroprotectionen
dc.subject.otherNon-steroidal anti-inflammatory drugen
dc.subject.otherPeptic ulceren
dc.subject.otherPreventionen
dc.subject.otherProton pump inhibitoren
dc.titleOne fifth of hospitalizations for peptic ulcer-related bleeding are potentially preventable.en
dc.typeJournal Articleen
dc.identifier.journaltitleWorld journal of gastroenterology : WJGen
dc.identifier.affiliationRay Boyapati, Sim Ye Ong, Bei Ye, Rhys Vaughan, Mayur Garg, Gastroenterology and Liver Transplant Unit, Austin Hospital, Melbourne, Victoria 3128, Australiaen
dc.identifier.doi10.3748/wjg.v20.i30.10504en
dc.description.pages10504-11en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/25132768en
dc.type.austinJournal Articleen
Appears in Collections:Journal articles
Show simple item record

Page view(s)

4
checked on May 7, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.